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Human milk oligosaccharides are unconjugated complex glycans present in high
concentration in human milk that serve as pre-biotics and immunomodulators. They
are not primarily absorbed or metabolized by the infant and reach the lower part of
the intestinal tract unaltered. One of the main oligosaccharides found in human milk
is 2′-fucosyllactose (2′-FL). This study aimed to investigate the effects of daily oral
administration of 2′-FL in healthy suckling rats. From days 2 to 16 of life, rats were daily
given the oligosaccharide (2′-FL) or vehicle (REF), weighed and their stool characteristics
were assessed. On days 8 and 16 of life the morphometry, intestinal architecture, and
cytokine release, mesenteric lymph nodes cell composition, plasma immunoglobulin
concentrations, fecal microbiota composition, cecal short-chain fatty acids content, and
the urinary metabolic profile were assessed. Animals given 2′-FL showed higher plasma
IgG and IgA and more T cell subsets in the mesenteric lymph nodes on day 16. Moreover,
at intestinal level, villus heights, and areas were increased on day 8. Cecal samples
displayed a higher Lactobacillus proportion and a different urinary metabolic profile was
observed on day 8, and a higher proportion of butyrate on day 16. In conclusion,
supplementation of 2′-FL in early life has a pre-biotic and intestinal trophic effect and
promotes maturation of the immune system.
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INTRODUCTION
Human milk provides all the essential nutrients to newborn and developing infants, as
well as bioactive compounds such as human milk oligosaccharides (HMOs), which promote
health benefits beyond nutrition (1). HMOs are produced in the mammary gland from
the monosaccharides galactose, glucose, N-acetylglucosamine, fucose, and sialic acid, forming
unconjugated complex glycans consisting of both short chain as well as long chain structures (in
9:1 ratio), that range from 10 to 15 g/L in mature milk (2). The presence of fucose and sialic acid
renders the HMOs resistant to digestion, thus allowing them to reach the large intestine of an infant
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unaltered (2, 3). Moreover, ∼1% of the ingested HMOs are
absorbed, reach the systemic circulation and are excreted in urine
without being metabolized (2).
To date, more than 200 HMOs having 3–22 monosaccharide
units have been identified. The secretor and the Lewis blood
group status direct the amount and type of oligosaccharides
present in the milk (4). In this respect, 2′-fucosyllactose (2′-FL)
is the major short chain HMO found in the milk of secretor
(FUT2)-positive women, accounting for more than 30% of the
total HMOs mixture (5). The concentration of 2′-FL in human
milk remains stable in the first month post-delivery; afterwards,
its concentration declines (3).
2′-FL has been demonstrated to confer beneficial effects both
in vitro and in vivo. These effects can be classified into two
groups, depending on whether they interact directly with host
cells and tissues or indirectly through their action on the gut
microbiota or pathogens (3). It has been shown that 2′-FL
has anti-inflammatory potential, for example by modulating
CD14 expression in human enterocytes and thus quenching
inflammatory signaling (5), or by reducing the concentration
of plasma inflammatory cytokines in infants (6). Numerous
intestinal pathogens employ the host oligosaccharide sequences
found on the cell surface of enterocytes to adhere as the first
step in the infection process. Because HMOs, such as 2′-FL,
also have a carbohydrate structure, they can act as soluble
receptor analogs and prevent the pathogen from infecting the
host (7). In this regard, 2′-FL has been shown to inhibit
the adhesion or infectivity of microbes, namely Campylobacter
jejuni (8), Enteropathogenic Escherichia coli (9), rotavirus
(10), and norovirus (11). In addition, supplementation of
infants with HMOs promotes a healthy microbiome dominated
by bifidobacteria and Bacteroidetes, which have the specific
glycosidases to utilize them as a source of energy. Contrarily,
most pathogenic Enterobacteriaceae do not have these enzymes
and thus, their growth is inhibited (12). Specifically, 2′-FL has
been shown to be a preferred substrate for bacteria isolated
from human gut, such as Bifidobacterium longum subsp. infantis,
Bifidobacterium bifidum, Bacteroides fragilis, and Bacteroides
vulgatus (13, 14). Accordingly, these bacteria produce short-chain
fatty acids (SCFAs) and other metabolites that may lower the gut
pH, impacting the composition of microbial communities and
limiting the growth and colonization of harmful microorganisms,
such as some pathogenic species of bacteroides, clostridia and
coliforms (3, 15–17).
A great part of the literature focuses on assessing the effects
of complex HMO mixtures, thus not enabling their individual
properties to be deciphered. In fact, there are only a few clinical
studies that have assessed the effects of the supplementation of
formulas with 2′-FL (18, 19). These studies provide evidence
that supplementation with 2′-FL is safe, well-tolerated and that
the infant’s growth is comparable with that of a breastfed
infant. However, there is limited evidence on the specific health
improvements of 2′-FL and its mechanism of action. Moreover,
although 2′-FL seems to be a good candidate to be considered as
a pre-biotic, there is still not enough data to support this (20).
Therefore, the present study aimed to investigate the effects
of daily supplementation with 2′-FL in healthy suckling rats.
To achieve this, we assessed intestinal and systemic parameters
in relation to animal growth, immune system, intestinal
architecture, microbiota composition, and metabolism.
MATERIALS AND METHODS
Animals
Pregnant Lewis rats (LEW/OrlRj, N = 6) with 15 days of
gestational age (G15) were obtained from Janvier Labs (Le
Genest-Saint-Isle, France) and individually housed in cages
(2184L Eurostandard Type II L, Tecniplast, West Chester, PA,
USA) containing bedding of large fibrous particles (Souralit
1035, Bobadeb S.L., Santo Domingo de la Calzada, Spain) and
tissue papers (Pañuelos desmaquillantes, Gomà-Camps S.A.U.,
La Riba, Spain). Pregnant rats were monitored daily and allowed
to deliver at term. The day of birth was established as day 1 of
life. On day 2, litters were randomly assigned to the experimental
groups (three dams with their litters/group) and culled to eight
pups per lactating dam, with a similar number of each sex
in each litter, and with free access to maternal milk and rat
diet. Dams were given a standard diet corresponding to the
American Institute of Nutrition 93G formulation (21) (Teklad
Global Diet 2014, Envigo, Indianapolis, IN, USA) and water
ad libitum. To avoid influence of biological rhythms, animal
handling was performed on a scheduled basis during the first
hours of the light phase. Daily handling and oral administration
were performed after separating all the mothers and keeping
the pups in the home-cage. Afterwards, the dam was reunited
with the whole litter. Animals were housed under controlled
conditions of temperature and humidity in a 12 h light−12 h dark
cycle, in the Faculty of Pharmacy and Food Science animal facility
(University of Barcelona, Spain). All experimental procedures
were conducted in accordance with the institutional guidelines
for the care and use of laboratory animals and were approved
by the Ethical Committee for Animal Experimentation of the
University of Barcelona and the Catalonia Government (CEEA-
UB Ref. 74/05 and DAAM 3046, respectively), in full compliance
with national legislation following the EU-Directive 2010/63/EU
for the protection of animals used for scientific purposes.
Experimental Design and Sample
Collection
Neonatal rats and their respective dam were randomly
distributed into two groups (3 litters in each group). In the
2′-FL group, pups received by oral gavage 0.2 g of 2′-FL/100 g of
body weight (4.5 µL/g/day) from day 2; and in the REF group
pups received the same volume of mineral water (vehicle) also by
oral gavage. 2′-FL was produced by microbial fermentation, with
>90% purity and residual components in dry powder including
glucose, fucose, lactose, 3′-FL, difucosyllactose, and water
(provided by Danone Nutricia Research, The Netherlands). The
dose of 2′-FL was selected in basis of the daily consumption
per body weight of this particular HMO by a baby (22, 23)
and previous studies (24, 25), which in addition has been
demonstrated to be a safe dose in rats (26). Rat body weight was
monitored daily. Moreover, the naso–anal and tail lengths were
measured to determine the body/tail ratio. The body mass index
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(BMI) was calculated as body weight/length2 (g/cm2) and the Lee
Index was calculated as (weight0.33/length) × 1,000 (g0.33/cm).
Fecal samples were obtained daily after gentle abdominal
massage to determine changes in fecal weight and consistency
due to the supplementation with 2′-FL. Stool consistency was
scored in a blinded manner based on texture and amount as
follows: normal feces (1); soft feces (2); totally loose feces (3);
high amount of watery feces (4). On days 8 and 16 of life, half of
each litter (four randomly selected pups/dam) was euthanized
to obtain tissue samples. The weight of spleen, thymus, liver,
small intestine, and large intestine were recorded. Moreover, the
length of the small and large intestines was measured. Mesenteric
lymph nodes (MLNs) were obtained to study the proportion of
specific immune cell populations. Plasma samples were used to
determine the total systemic immunoglobulins (Igs). The small
intestine was rinsed with PBS. The central part was obtained
to quantify the relative gene expression of several genes and
a fragment of the distal jejunum to study histomorphometric
changes. The remaining parts of the small intestine were opened
lengthwise, cut into 5mm pieces, incubated with 2mL of PBS
in a shaker (10min, 37◦C) and then centrifuged in order to
obtain the gut wash (GW), which enabled to quantify the
intestinal cytokine release. Fecal samples were obtained on
day 8 by abdominal massage for the analysis of the microbiota
composition. Moreover, short-chain fatty acids (SCFAs) were
analyzed in the cecal content, at the end of the study. Finally,
for the metabolomic study, urine samples were post-mortem
directly obtained from the bladder by puncture.
Quantification of Immunoglobulins and
Cytokines
The quantification of Ig in plasma (IgM, IgG1, IgG2a, IgG2b,
IgG2c, and IgA) and cytokines in the gut wash (IL-1α, IL-4,
IL-6, IL-10, IL-12p70, IFN-γ, and TNF-α) was performed on
samples obtained in rats euthanized on days 8 and 16 of life, as
previously described (24). Briefly, specific color-coded capture
beads were bound to the analyte of interest. After adding different
detection antibodies conjugated to phycoerythrin (PE), for the
quantification of Ig, or biotin and adding afterwards streptavidin-
PE for the quantification of cytokines, the specific concentration
of each analyte was obtained by MAGPIX R© analyzer (Luminex
Corporation, Austin, TX, USA) at the Cytometry Service of
the Scientific and Technological Centers of the University of
Barcelona (CCiT-UB).
Isolation of Mesenteric Lymph Node Cells
MLN cells of 16-day-old rats were obtained by passing the
tissue through a sterile 40µm mesh cell strainer (Thermo
Fisher Scientific, Barcelona, Spain) placed on a Petri dish
on an ice surface and containing Roswell Park Memorial
Institute (RPMI) 1640 medium (Sigma-Aldrich, Madrid, Spain)
enriched with 10% fetal bovine serum (FBS, Sigma-Aldrich),
100 IU/mL streptomycin-penicillin (Sigma-Aldrich), 2mM L-
glutamine (Sigma-Aldrich), and 0.05mM 2-β-mercaptoethanol
(Merck Millipore, Darmstadt, Germany). The suspension was
centrifuged (538 g, 10min, 4◦C) and resuspended in the enriched
RPMI. The number and viability of cells were determined by
CountessTM Automated Cell Counter (InvitrogenTM, Thermo
Fisher Scientific).
Immunofluorescence Staining and Flow
Cytometry Analysis
MLN cell suspensions (3 × 105 cells) were stained using
fluorochrome-conjugated monoclonal antibodies (mAbs). The
mouse anti-rat mAb conjugated to fluorescein isothiocyanate
(FITC), phycoerythrin (PE), peridinin chlorophyll protein
(PerCP), or allophycocyanin (APC) used here included anti-
CD4 (OX-35), anti-CD8α (OX-8), anti-TCRαβ (R73), anti-
TCRγδ (V65), and anti-NKR-P1A (10/78), all from BD
Biosciences (San Diego, CA, USA); anti-CD45RA (OX-33) from
Caltag (Burlingame, CA, USA); anti-CD8β (3·41) from Serotec
(Kidlington, Oxford, UK); anti-αE integrin (OX-62) and anti-
CD62L (OX-85) from BioLegend (San Diego, CA, USA). Staining
was performed as previously described (27). Results were
acquired using a GalliosTM flow cytometer (Beckman Coulter
Inc., Madrid, Spain) in the Cytometry Service of the CCiT-UB.
The data obtained were analyzed with FlowJo 10.0.7 software
(Tree Star Inc., Ashland, OR, USA).
Quantification of Intestinal Gene
Expression
A portion of about 0.5 cm of the central section of the small
intestine of 8-day-old rats was homogenized for 30 s in lysing
matrix tubes (MP Biomedicals, Illkirch, France) using a FastPrep-
24 instrument (MP Biomedicals), as previously described (28).
RNA was isolated with the RNeasy R© Mini Kit (Qiagen, Madrid,
Spain) following the manufacturer’s instructions. RNA purity
and concentration were determined with a NanoPhotometer
(BioNova Scientific S.L., Fremont, CA, USA). Later, cDNA was
obtained using thermal cycler PTC-100 Programmable Thermal
Controller and TaqMan R© Reverse Transcription Reagents
(Applied Biosystems, AB, Weiterstadt, Germany).
The specific PCR TaqMan R© primers (AB) used to assess gene
expression with real-time PCR (ABI Prism 7900 HT, AB) were
pIgR (Rn00562362_m1, I), Iga (331943, made to order), Tlr2
(Rn02133647_s1, inventoried [I]), Tlr3 (Rn01488472_g1,
I), Tlr4 (Rn00569848_m1, I), Tlr5 (Rn04219239_s1, I),
Tlr7 (Rn01771083_s1, I), Tlr9 (Rn01640054_m1, I), Ifng
(Rn00594078_m1, I), Tnf (Rn99999017_m1, I), Tgfb1
(Rn00572010_m1, I), Il10 (Rn00563409_m1, I), Il17a
(Rn01757168_m1, I), Il22 (Rn01760432_m1, I), Muc2
(Rn01498206_m1, I), Ocln (Rn00580064_m1, I), Cldn2
(Rn02063575_s1, I), Fcgrt (Rn00583712_m1, I, encoding for
FcRn), and Prdm1 (Rn03416161_m1, I, encoding for Blimp-1).
The relative gene expression was normalized to the housekeeping
gene Gusb (Rn00566655_m1, I) using the 2−11Ct method (29).
Results were expressed as the percentage of expression in each
experimental group normalized to the mean value obtained for
the REF group, which was set at 100%.
Histomorphometric Analysis
Intestinal distal jejunum samples of rats sacrificed 8 days
after birth were dehydrated, paraffin-embedded, sectioned, and
stained with hematoxylin-eosin, as previously described (24).
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Intestinal architecture was analyzed by bright-field microscopy
(Olympus BX41, Olympus Corporation, Shinjuku, Tokyo, Japan)
at 100× magnification. The intestinal perimeter was calculated
by measuring the outer layer of the intestine. Seven villi from
each animal were randomly selected and villus heights and areas
were measured. Villus widths were measured at the crypt-villus
junction. Crypt depths and the ratio villus heights to crypt
depths were calculated. Statistical analysis was performed with
each animal’s mean value of the parameters described above.
All morphometric measurements were performed with ImageJ
(Image Processing and Analysis in Java, National Institute of
Mental Health, Bethesda, MD, USA).
Fecal Microbiota Composition
Genomic DNA was extracted from day-8 fecal samples ranging
5–20mg, using Qiamp DNA Stool Mini kit (Qiagen), enzymatic
lysis and mechanic disruption (30). Extra purification and
concentration were performed following the cleaning protocol
from Qiamp Micro kit (Qiagen). Fifty ng of DNA were amplified
following the 16S Metagenomic Sequencing Library Illumina
15044223 B protocol (Illumina Inc, San Diego, CA, USA) and
sequences were merged and processed using Pair-End read
merger (PEAR v 0.9.6, Exelixis Lab, Heidelberg, Germany) and
Cutadapt v1.8.1 (31).
To estimate the specific biodiversity, the Shannon–Wiener
and CHAO1 indexes were calculated. In order to study the
presence or absence of taxonomic ranks (family, genera and
species) in the experimental groups, it was agreed that all groups
displaying two or three animals (out of the three randomly
analyzed in each group) with some bacterial proportion were
computed as present, while the groups displaying one animal or
none were computed as absent. Venn diagrams and heat maps
based on log2 fold change with respect to 2′-FL were represented.
Moreover, principal components analysis (PCA) was conducted
to search for natural clustering of the samples with Matlab
(MathWorks, Natick, MA, USA) using in-house scripts.
Quantification of Short-Chain Fatty Acids
in the Cecal Content
The quantification of cecal SCFAs in neonatal rats of 16 days
of life was performed by headspace-gas chromatography-mass
spectrometry (HS-GC-MS) at the GC-MS unit of the CCiT-
UB, as previously described (24). Acetic, propionic, isobutyric,
butyric, isovaleric, valeric, isocaproic, caproic, and heptanoic
acids were quantified.
Metabolomic Analysis of Urine
Urine samples of 16-day-old rats (six random samples from
each group obtained immediately after sacrifice) were thawed
at room temperature and homogenized using a vortex mixer.
Five hundred microliters of phosphate buffer (pH 7.4; 100%
D2O) containing 1mM of the internal standard, 3-trimethylsilyl-
1-[2,2,3,3-2H4] propionate (TSP) were added to 100 µl of
urine. Samples were mixed and centrifuged (10,000 g, 10min,
room temperature) before transfer to a 5.0mm nuclear magnetic
resonance (NMR) tube. All samples were analyzed on a 600
MHz Bruker Avance III NMR spectrometer equipped with a
5mm PABBO BB-1H/D Z-GRD probe and a SampleJet robot
(Bruker Biospin, Germany). Standard one-dimensional 1HNMR
spectra of the urine samples were acquired using a standard
one-dimensional NOESY pre-saturation pulse sequence (Bruker
sequence code noesypr1d). Water resonances were suppressed
with irradiation at the water frequency during both the recycle
delay of 5 s and the mixing time of 100ms. For each sample,
a total of 256 scans were collected in 64K data points with a
spectral width of 16 ppm and an acquisition time of 3.42 s. Two-
dimensional 1H–1H correlation spectroscopy (COSY), 1H–1H
total correlation spectroscopy (TOCSY), 1H–13C heteronuclear
single quantum coherence (HSQC) and J-resolved NMR spectra
were acquired to aid metabolite identification in addition to
statistical total correlation spectroscopy (STOCSY). The free
induction decay was multiplied by an exponential weighting
function corresponding to 0.3Hz line broadening prior to
Fourier transform. Spectra were manually phased and corrected
for baseline distortions using Topspin 3.5. All spectra were
referenced to the TSP singlet at δ 0.0. 1H NMR spectra (δ 0.2–
10.0) were digitized into consecutive integrated spectral regions
(∼20,000) of equal width (0.00055 ppm). The regions between δ
4.50–5.00 and 5.58–5.95, containing the residual water and urea
peaks, respectively, were removed in order to minimize baseline
effects caused by imperfect water suppression. Each spectrum
was then normalized to unit area to account for variation in the
sample concentration. All 1H NMR spectra were then aligned
using a recursive segment-wise peak alignment method. Three
urine samples contained a high amount of bladder tissue and they
had to be discarded from the analysis.
PCA with mean centering and pareto scaling was performed
in in Matlab using in-house scripts in order to visualize patterns,
clusters and outliers within the data set (32). Then, 1H NMR
spectroscopic profiles were used as the descriptor matrix (X) and
class membership (e.g., REF or 2′-FL) was used as the response
variable (Y) to perform an orthogonal projection to latent
structures-discriminant analysis (OPLS-DA) with unit variance
scaling, as in previous studies (33).
Statistical Analysis
Analysis of data was performed with the Statistical Package
for the Social Sciences (SPSS v22.0) (IBM, Chicago, IL, USA).
Data were tested for homogeneity of variance and normality
distribution by the Levene’s and Shapiro–Wilk tests, respectively.
When there was equality of variance and a normal distribution
of data, conventional unpaired t-test was performed. Otherwise,
the non-parametric Kruskal–Wallis test followed by the post hoc
Mann–Whitney U (MWU) test were performed. Significant
differences were established when p < 0.05.
Sample size estimation was calculated by the Appraising
Project Office’s program from theUniversidadMiguel Hernández
de Elche (Alicante). The minimal sample size to provide
statistically significant differences among groups, using plasma
IgG as variable and assuming that there is no dropout rate
and type I error of 0.05 (two-sided), was three litters, as in
previous studies, because of the remarkable variability among
litters (34, 35).
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TABLE 1 | Effect of 2′-FL supplementation on the immunoglobulin levels in plasma.
Day 8 Day 16
µg/mL REF 2′-FL REF 2′-FL
IgM 5.65 ± 0.19 5.74 ± 0.31 19.49 ± 0.75 18.83 ± 1.15
IgG 2123.26 ± 78.15 2454.14 ± 76.43* 3693.28 ± 180.15 5732.33 ± 284.11*
IgG1 112.53 ± 3.00 105.36 ± 7.14 273.60 ± 6.67 296.84 ± 33.20
IgG2a 476.66 ± 24.12 483.95 ± 12.71 722.84 ± 17.44 884.24 ± 25.87*
IgG2b 558.21 ± 51.12 834.30 ± 37.10* 1055.80 ± 26.15 2452.3 ± 166.19*
IgG2c 975.86 ± 78.55 1030.52 ± 28.18 1641.03 ± 170.39 2098.97 ± 79.03*
Th1/Th2 2.65 ± 0.18 3.16 ± 0.05* 2.71 ± 0.18 3.85 ± 0.17*
IgA 38.88 ± 3.06 45.37 ± 1.88 63.32 ± 1.49 90.15 ± 3.37*
Results are expressed as mean ± S.E.M. (n = 8/group).
*p < 0.05 compared to REF (by Mann–Whitney U-test).
Th1/Th2 = (IgG2b+IgG2c)/(IgG1+IgG2a).
REF, Reference; 2′-FL, 2′-fucosyllactose.
RESULTS
Growth and Fecal Characteristics
Body weight was monitored daily throughout the study
(Supplementary Figure 1). Animals given 2′-FL had similar
weights compared to REF animals, although at the end of
the study a slightly higher body weight was found (p <
0.05, Supplementary Table 1). Body mass and Lee indexes were
comparable between 2′-FL and REF group, whereas a higher
body-to-tail-length ratio was found in the 2′-FL group on both
day 8 and day 16 (Supplementary Table 1). The intake of 2′-FL
did not influence the size of the organs studied (spleen, thymus,
liver, and intestines), with the exception of a relatively lower
colonic weight on day 16 (p < 0.05).
With regard to stool characteristics, supplementation with 2′-
FL did not affect stool weight (REF: 4.3 ± 0.48mg on day 8 and
7.5± 0.65mg on day 16 vs. 2′-FL: 5.5± 0.69mg on day 8 and 9.8
± 0.93mg on day 16). In addition, stool samples were scored in
all cases with a score of 1 (scale 1–4) on days 8 and 16, indicating
no changes in the fecal consistency due to the intervention.
Total Immunoglobulins
Plasma concentration of Ig classes and subclasses were quantified
on days 8 and 16 (Table 1). 2′-FL supplemented animals showed
elevated plasma IgG concentration on day 8, primarily due to a
50% increase in IgG2b (p< 0.05). Accordingly, 2′-FL promoted a
shift to Th1 response by increasing the Th1/Th2 immunoglobulin
ratio (p < 0.05, IgG2b+IgG2c/IgG1+IgG2a). The Ig analysis on
day 16 not only maintained the effects found on day 8, but also
increased significantly the levels of IgG2a and IgG2c (p < 0.05).
Moreover, 2′-FL supplementation raised plasma IgA levels by
more than 40% compared to the REF group on day 16 (p< 0.05),
but no effect on IgM was found.
Mesenteric Lymph Node Cell Subsets
The relative proportion of MLN cell subsets was analyzed on
day 16 (Table 2). The neonatal rats administered daily with 2′-
FL showed an increase in the proportion of T cells whereas that
of B cells decreased (p < 0.05), giving rise to a deviation of the
TABLE 2 | Effect of 2′-FL supplementation on the mesenteric lymph node
immune cells proportion on day 16.
Populations in MLN (%) REF 2′-FL
B cells (CD45RA+) 30.53 ± 2.54 18.13 ± 2.19*
T cells (Th and Tc cells) 62.01 ± 2.12 74.97 ± 2.03*
Th cells (CD4+ TCRαβ+ NK–) 46.21 ± 1.32 55.56 ± 1.45*
CD62L+ 23.46 ± 3.10 29.33 ± 1.80*
CD25+ 2.15 ± 0.53 2.64 ± 0.08
Tc cells (CD8+ TCRαβ+ NK- and TCRγδ+) 15.80 ± 0.81 19.41 ± 0.62*
TCRαβ+ (CD8+ TCRαβ+ NK–) 13.65 ± 0.81 16.91 ± 0.60*
TCRγδ+ 2.15 ± 0.04 2.50 ± 0.05*
CD8+ 1.52 ± 0.02 1.84 ± 0.06*
CD8– 0.62 ± 0.05 0.66 ± 0.05
NKT cells (TCRαβ+ NK+) 2.99 ± 0.46 3.08 ± 0.22
CD8+ 1.72 ± 0.27 1.84 ± 0.11
CD8– 1.27 ± 0.19 1.24 ± 0.14
NK cells (TCRαβ- NK+) 3.43 ± 0.62 2.75 ± 0.16
CD8+ 0.47 ± 0.11 0.50 ± 0.05
CD8– 2.96 ± 0.51 2.25 ± 0.13
Results are expressed as mean ± S.E.M. (n = 4/group).
*p < 0.05 compared to REF (by Student T-test).
Th, T-helper; Tc, T-cytotoxic; NK, Natural Killer; NKT, Natural Killer T; REF, reference;
2′-FL, 2′-fucosyllactose.
T/B ratio (p < 0.05, REF: 2.06 ± 0.17, 2′-FL: 4.33 ± 0.53). This
increase in T cells was linked to both higher T-helper (Th) and
T-cytotoxic (Tc) cell proportions (p < 0.05). The administration
of 2′-FL increased the percentage of Th lymphocytes expressing
the adhesion molecule CD62L (p < 0.05), but not of those Th
expressing the activation marker CD25. The increase in Tc cells
was both in TCRαβ+ and TCRγδ+ subsets (p< 0.05). Moreover,
no changes were observed in the proportion of NKT and NK cell
subsets and in their co-expression of CD8 in rats receiving 2′-FL
as compared to control. In addition, the expression of CD8, used
as overall marker of immune maturation, was also analyzed in
the entire population of lymphocytes (Figure 1). In this regard,
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FIGURE 1 | Effect of 2’-FL on CD8 surface expression in the mesenteric lymph node lymphocytes. (A) Percentage of lymphocytes expressing CD8. (B) Percentage of
CD8+ lymphocytes expressing CD8αα or CD8αβ. (C) Ratio between the percentage of CD8αα and CD8αβ subsets. Results are expressed as mean ± S.E.M. (n =
4/group). *p < 0.05 compared to REF group (by Student T-test). REF, Reference (REF); 2′-FL, 2′-fucosyllactose.
the rats receiving 2′-FL displayed a higher proportion of total
CD8+ lymphocytes, which in turn were composed of a higher
proportion of CD8αβ+ cells and a lower proportion of CD8αα+
cells, compared to the REF rats (p < 0.05). As a result, the 2′-FL
group presented a lower CD8αα/CD8αβ ratio (p < 0.05).
Intestinal Gene Expression and Cytokine
Production
Expression levels of genes involved in the activity of the
immune system and gut barrier function were assessed on day
8 (Figure 2A). Supplementation with 2′-FL did not modify the
expression of genes linked to IgA secretion (pIgR, IgA), Toll-
like receptors (TLR2, 3, 4, 5, 7, and 9), cytokines (TNF-α, IL-
22, IFN-γ, IL-10, TGF-β), epithelial barrier function molecules
(Muc2, Ocln, and Cldn2) or the status of intestinal function
(FcRn and Blimp-1). However, there was an overall trend (p =
0.2) toward increased expression levels of most TLR genes (with
the exception of TLR4 and TLR9), with an increase in mean
expression levels ranging between 20 and 125% in the 2′-FL
group compared to the REF group.
Quantification of cytokines in the gut wash was performed
on samples from both days 8 and 16 (Figures 2B,C). Animals
who received 2′-FL displayed similar concentrations of cytokines
compared to the REF animals on day 8, but not on day 16.
Specifically, the 2′-FL group displayed lower levels of almost all
cytokines quantified (IL-1β, IL-4, IL-6, IL-12, IFN-γ, and TNF-
α), which were nearly half of those levels found in the REF group
(p < 0.05). No changes were observed in the ratio of Th1/Th2
cytokines based on the proportion of IFN-γ/IL-4 (REF: 20.58 ±
1.08 on day 8 and 23.13± 8.78 on day 16; 2′-FL: 20.91± 0.34 on
day 8; and 23.59± 4.36 on day 16).
Intestinal Histomorphometry
The effects of 2′-FL on several intestinal histomorphometric
parameters were assessed on day 8 (Figure 3). Animals receiving
2′-FL displayed higher villus heights and villus areas compared to
the REF group (p< 0.05). Although no statistical differences were
found in the villus widths, a tendency toward increased villus
widths was observed after 2′-FL supplementation. Neither the
intestinal perimeter nor crypts depths showed any remarkable
changes, but villus/crypt ratios were increased (p < 0.05),
primarily due to higher villus heights.
Fecal Microbiota Composition
The fecal microbiota composition was studied on day 8 (Figure 4
and Supplementary Figure 2). The diversity of microbial
populations, assessed with the Shannon–Wiener and CHAO1
indexes, did not show any significant differences between
the REF and the 2′-FL groups (REF: 1.68 ± 0.08 and 260
± 50, 2′-FL: 1.63 ± 0.03, and 200 ± 17, respectively). The
supplementation with 2′-FL displayed changes in bacterial
proportions at the taxonomic levels of phylum, family, genera,
and species (Figure 4A). At the level of phylum, the proportion
of Actinobacteria was lower, while that of Firmicutes was higher
in the 2′-FL group compared to the REF group (p < 0.05). On
the one hand, the increase in Firmicutes was primarily due to an
increase in the Lactobacillaceae family, in particular Lactobacillus
genus (p < 0.05). In this regard, many of the Lactobacillus
species already present in the REF group displayed a tendency
to increase their levels after dietary supplementation with 2′-FL,
and in addition, nine new species of Lactobacillus appeared
(Supplementary Figure 2). On the other hand, the decrease
in Actinobacteria was linked to a lower proportion of Rothia,
belonging to the Micrococcaceae family (p < 0.05, Figure 4A)
and to the absence of nine species, which were only found in the
REF group (Supplementary Figure 2). Moreover, a decrease in
less abundant families of Firmicutes, such as Enterococcaceae and
Streptococcaceae, was observed after the supplementation with
2′-FL (p < 0.05). At the level of species, Escherichia fergusonii
and Lactobacillus animalis were the most abundant populations
in both REF and 2′-FL groups, accounting for ∼80% of the total
fecal microbiota.
The PCA at the level of families (Figure 4B) revealed that
the animals supplemented with 2′-FL clustered apart from those
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FIGURE 2 | Effect of 2′-FL on the intestinal gene expression and production of cytokines. (A) The intestinal function was assessed on day 8 by the relative
quantification of IgA secretion, Toll-like receptors, cytokines, epithelial barrier, and maturation by real-time PCR. The relative gene expression in the experimental
groups was calculated with respect to REF, which corresponded to 100% of transcription (indicated with a horizontal dotted line). A collection of cytokines (IL-1β, IL-4,
IL-6, IL-10, IL-12, IFN-γ, TNF-α) were quantified in the intestinal wash of animals on (B) day 8 and (C) day 16 of life. Results are expressed as mean ± S.E.M. (n =
8/group in (A), n = 6/group in (B,C) *p < 0.05 compared to REF group (by Mann-Whitney U-test). pIgR, Polymeric immunoglobulin receptor; IgA, immunoglobulin A;
TLR, Toll-like receptor; TNF, tumor necrosis alpha; IL, interleukin; IFN, interferon; TGF-β, tumor growth factor-beta; MUC2, mucin 2; Ocln, occludin; Cldn2, claudin 2;
FcRn, neonatal constant fragment receptor; Blimp-1, B-lymphocyte-induced maturation-protein-1; REF, reference; 2′-FL, 2′-fucosyllactose.
of the REF group, as depicted by the lack of overlapping in
the Hotelling’s T2 95% confidence ellipses, indicating that the
supplementation induced a different microbiota composition.
In order to gain a deeper understanding of the presence or the
absence of bacterial groups after 2′-FL supplementation, Venn
diagrams were represented for the number of families and genera
(Figure 4C). There was a core of 21 families and genera that
were present in both groups. Nevertheless, the supplementation
with 2′-FL promoted the colonization with nine families and
15 species, like the previously mentioned Lactobacillus, and
prevented those of six families and nine genera compared
to the REF group. Some butyrate-producing bacteria, such as
Roseburia, Ruminococcus, and Blautia appeared only after the
supplementation with 2′-FL (Supplementary Figure 2).
Cecal SCFA Production
The quantification of SCFAs in the cecal content was performed
at the end of the study (day 16), enabling the changes after the 15-
day supplementation to be observed (Figure 5). The 2′-FL group
displayed lower total SCFA levels compared to the REF group
(9.7± 1.89 and 17.1± 1.05 µM/g, respectively), mainly linked to
a reduction of acetic and propionic acids (p < 0.05, REF: 11.35
± 0.77 and 4.85 ± 0.30 µM/g; 2′-FL: 6.10 ± 1.4 and 2.56 ±
0.49µM/g, for acetate and propionate, respectively). Besides that,
when calculating their relative proportion (Figure 4), all SCFAs
displayed similar values compared to the REF group, with the
exception of butyric acid, the proportion of which was two-fold
greater in the 2′-FL group than in the REF animals (p < 0.05).
Metabolomic Analysis of Urine
The metabolomic analysis of urine was performed on day 16.
Initially, an unsupervised analysis was performed to obtain a
general overview of the natural data grouping and to show
similarities in metabolic profiles (Figure 6). A four-component
PCAmodel from all urine samples explained 77% of the variation
in the data and the scores plot of the two first principal
components showed an apparent separation between REF and
2′-FL animals.
Metabolites significantly contributing to separation
between REF and 2′-FL were identified from the OPLS-DA
coefficients loading plot (Figure 6). Rats receiving 2′-FL
excreted significantly higher amounts of tricarboxylic acid
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FIGURE 3 | Effect of 2′-FL on intestinal histomorphometric variables on day 8. (A) Representative images of distal jejunum sections stained with hematoxylin and
eosin, 100×. (B) Villi height, villi width, villi area, crypts depth, villi height/crypts depth ratio, and perimeter of the jejunum of suckling rats. Results are expressed as
mean ± S.E.M. (n = 8/group). *p < 0.05 compared to REF group (by Student T-test). REF, Reference; 2′-FL, 2′-fucosyllactose.
(TCA) cycle metabolites (succinate, citrate, 2-oxoglutarate
[2-OG], and fumarate), metabolites from the nicotinate and
nicotinamide pathway (1-methylnicotinamide [NMND] and
N-methyl-2-pyridone-5-carboxamide [2-PY]), gut microbial
metabolites of choline (choline and dimethylglycine [DMG]),
creatine-related metabolites (creatine, guanidinoacetate [GAA]),
taurine, N-acetyl glycoproteins (NAG), and those related to
the oligosaccharide (fucose and 2′-fucosyllactose). Metabolites
identified as contributing to separation between treatments
through the OPLS-DA model were integrated and spectral peak
integrals were further analyzed for statistical significance using
univariate methods (Supplementary Table 2).
DISCUSSION
There is evidence supporting the beneficial effects of HMOs
in early life, for example by modulating the immune system,
changing the microbial composition, or protecting against
infections (4, 36, 37). The present study gained insights into the
effects of 2′FL supplementation, showing improved maturation
of the immune system, gut trophic effects and as well as
supporting the development of a balanced gut microbiome. The
nutritional intervention with 2′-FL did not show biologically
relevant changes in the growth of the animals compared to the
REF group, as similarly evidenced in other studies (18, 19, 26,
38). In addition, the relative weights of the organs analyzed
and the stool characteristics were not affected after 15 days of
supplementation, confirming that their administration was safe
and well-tolerated, which is in line with studies performed by
other authors (26, 39). The histomorphometric analysis of the
small intestine revealed that administration of 2′-FL for 7 days
had an intestinal trophic effect as observed by higher villus
heights and areas. Conflicting results have been reported by
others showing higher villus heights after administering 2′-FL to
newborn pigs infected with E. coli (40) or after extensive intestinal
resection in mice (41). Other studies did not find any alterations
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FIGURE 4 | Effect of 2′-FL on the fecal microbiota composition on day 8. The sequencing of the amplicon targeting the V3–V4 region of the 16S rRNA was performed
following the 16S Metagenomic Sequencing Library Illumina 15044223 B protocol. The relative proportion of the bacteria was calculated for (A) phylum, family, genus,
and species. (B) PCA of the proportion of bacteria at the level of family. (C) Venn Diagrams showing the number of families and genera in the REF and 2′-FL groups.
Results are expressed as the mean value (n = 3/group, corresponding to one random animal/litter). *p < 0.05 compared to REF group (by Mann–Whitney U-test).
REF, Reference; 2′-FL, 2′-fucosyllactose.
of the gut histomorphometry after 2′-FL supplementation in RV-
infected piglets (42) or in preterm pigs (43). Overall, the present
study showed positive effects on intestinal growth after 2′-FL
supplementation which might impact the absorptive capacity of
the animals.
Human milk oligosaccharides (HMOs) are known to
influence the mucosal and systemic immunity, either directly
by interacting with the immune cells, or indirectly, for example
through the microbiota (36). We assessed the effects on
the immune system with regard to both the humoral and
cellular arms after the supplementation with 2′-FL. The animals
supplemented with the oligosaccharide already displayed higher
levels of circulating IgGs on day 8. This effect was stronger on
day 16, when in addition to the higher IgGs, an increase in IgA
was also detected. A recent study has also evidenced an increased
IgG response after the vaccination of mice supplemented with
2′-FL with influenza virus (44). When considering the IgG
subclasses, it was observed that 2′-FL supplementation promoted
an increase in the Th1-type immunoglobulins compared to Th2-
type, increasing the Th1/Th2 ratio. Accordingly, at birth, the
immune system is biased toward a Th2 phenotype, which is
linked to promoting humoral responses, as opposed to that of
the immature cellular immunity (45). As the immune system
matures, the response switches toward a Th1 phenotype (46).
Therefore, the increase in Th1 immunoglobulins would suggest
that 2′-FL promotes the maturation of the immune system in
early life.
Because the major effects of 2′-FL are supposed to be exerted
in the intestine or its surroundings, we evaluated the immune cell
subsets in the MLNs and the intestinal production of cytokines.
Herein, we have shown that the HMO 2′-FL promoted higher
T cell and lower B cell proportions in MLNs on day 16 of life.
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FIGURE 5 | Effect of 2′-FL on the cecal SCFA production on day 16. Acetic, propionic, butyric, isobutyric, valeric, and isovaleric acid production was quantified by
HS-GC-MS. Results are expressed as the mean relative percentage ± S.E.M. (n = 8/group). *p < 0.05 compared to REF group (by Mann-Whitney U-test). REF,
Reference; 2′-FL; 2′-fucosyllactose.
FIGURE 6 | Effect of 2′-FL on the urinary metabolic profile on day 16. (A) NMR spectra was analyzed by natural clustering by PCA. (B) OPLS-DA coefficient plot
showing the most significant metabolites. In this plot, positive peaks represent metabolites excreted at higher concentrations in urines of rats which received 2′-FL
supplementation compared to the REF group, whereas negative peaks indicate metabolites excreted in higher concentration in the REF group (n = 4–5/group). REF,
Reference; 2′-FL, 2′-fucosyllactose.
It can be suggested that B cells may be migrating from the
MLN to the systemic compartment or becoming plasma cells,
because despite observing a relative decrease in B cell proportion
in MLN, this was not linked to a decrease in the production of
Ig, as their circulating levels were elevated. In fact, the values
displayed by the animals receiving the oligosaccharide more
closely resembled those also found in healthy Lewis suckling
rats of 19 days of life (47), suggesting that 2′-FL may accelerate
intestinal immune cell maturation. The rise in T cell proportion
was due to both Th and Tc cells increases, further supporting
the concept that 2′-FL drives the age-related switch to Th1
phenotype, since Tc cells are generated with the aid of this
type of response. A particular subset of Tc cells, γδ T cells,
pre-dominate during fetal and early life, and are important for
mounting rapid innate responses against exogenous pathogens
in the gut (48, 49). The CD8+ γδ T cell subset proportion
was increased after the supplementation with 2′-FL, again
supporting the idea that the oligosaccharide influences immune
maturation. This was in agreement with Grases-Pintó et al.,
who found an increase of this subset in MLNs of rats aged
14–21 days (50). On the contrary, Comstock et al. did not
find any differences in Th or Tc subsets in pigs fed an HMO
mixture containing 2′-FL, but found increased proportions of
memory effector T cells in MLNs of 15-day-old piglets (38).
Moreover, recent data supports that 2′-FL improves innate and
adaptive cellular immunity, for example by expanding vaccine-
specific splenic CD4+ and CD8+ T cells and inducing optimal
Th1 responses (44). Finally, the increase in the total CD8
lymphocytes and the decreased CD8αα/CD8αβ ratio, biomarkers
of intestinal immune maturation described in previous studies
(50), also evidence that 2′-FL promoted an accelerated intestinal
immune maturation.
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We observed a general decrease of intestinal cytokines on day
16, but not on day 8. This evidenced that immunomodulation
at the cellular level was either depending on the 2′FL dose,
as the total amount received on day 16 is higher than on
day 8, or that the effects are time-dependent. Several of the
cytokines that were reduced after 2′-FL supplementation are
highly inflammatory (IL-1β, IL-6, IFN-γ), and this therefore
supports the anti-inflammatory potential of the oligosaccharide.
In fact, a randomized controlled trial found that circulating
plasma concentrations of these cytokines are higher in standard
formula-fed infants, and that infants fed a formula containing
2′-FL have lower concentrations of inflammatory cytokines at
comparable levels to those found in breastfed infants (6).
The microbiota of the newborn is characterized by low
diversity and rapid transformation. Facultative aerobic species
colonize the intestine initially, and as the oxygen is consumed,
they are replaced by anaerobic species (51–53). Herein, we
have evidenced that the fecal microbiota of 8-day-old rats
was dominated by the phyla Firmicutes, Proteobacteria, and
Actinobacteria, with Escherichia, Lactobacillus, and Rothia being
the genera accounting for more than 90% of the microbiota. The
PCA analysis revealed that those individuals who received 2′-FL
displayed a different microbiota compared to those that did not,
since both experimental groups clearly clustered apart.
We aimed to assess the pre-biotic effect of 2′-FL and found an
increase in Lactobacillus, but not in Bifidobacterium proportions.
Because HMOs are not extensively degraded by β-glucosidases
of lactobacilli (54), their increase does not seem to involve
direct catabolism. Studies using purified HMOs demonstrate
that most lactobacillus do not utilize 2′-FL as a carbon source
(55), although some strains such as L. acidophilus, L. plantarum,
and L. mesenteroides might be able to hydrolyze it weakly (56).
Therefore, it remains unclear the exact mechanism of the pre-
biotic effect of 2′-FL in the Lactobacillus population; some
other hypotheses, such as the changes observed in the host’s
immune system, microbial cross-feeding interactions or SCFA
production, may play a significant role. It is well-documented
that HMOs can be degraded by many strains of Bifidobacterium,
which are known to take part in the healthy microbiota of the
infant (57–59). However, the microbiota of the 8-day-old rat
showed a small proportion of these bacteria, most likely because
Bifidobacterium is a strictly anaerobe and it probably appears
later in life. Moreover, numbers of bifidobacteria seemed to start
increasing after approximately 14 days of supplementation (60),
which could explain why we did not find any differences earlier.
Nevertheless, 2′-FL showed a pre-biotic effect by increasing the
proportion of lactobacilli.
We also found a decrease of other facultative anaerobes
from the genera Streptococcus and Enterococcus. This fact,
together with a higher lactic acid bacteria, could suggest
that the microbiota is changing more rapidly after 2′-FL
supplementation, since after the first week of life, some
genera such as Staphylococcus and Enterococcus are known to
decrease (60).
The present study also aimed to assess the metabolic changes
after 2′-FL by means of assessing the intestinal SCFA production
and the urinary metabolomic profile of the rats. The bacterial
end-product SCFAs are produced after the metabolism of HMOs
in the gut (13, 61). Herein, we found that there was a reduction
in the concentration of total SCFAs in the 2′-FL group, which
may be due to lower production or to a higher absorption.
However, the relative amount of butyric acid in cecal content was
remarkably increased. Bifidobacteria are known to be one of the
main producers of lactate and acetate, the main SCFAs (13, 62).
The low counts of these types of bacteria may explain why we did
not find an increase in the total SCFAs. Besides, butyrate is well-
known for its health-promoting properties in the gut and has
been shown to be elevated after the supplementation with HMOs
(37). This SCFA may be involved in immune homeostasis, for
example by reducing pro-inflammatory pathways, such as STAT,
AP-1, and NF-κB (63, 64). Therefore, the increased butyrate
may be associated with the anti-inflammatory properties of 2′-FL
found in the present study as evidenced by reduction of intestinal
cytokine levels. In addition, the increase in butyrate after 2′-
FL supplementation could be related to the higher excretion
of tricarboxylic acid (TCA) cycle intermediates observed in the
urines of this group. Furthermore, butyrate has been shown to
be a histone deacetylase (HDAC) inhibitor and thus potentially
increases the acetylation of a wide number of metabolic proteins,
and nearly every enzyme involved in the TCA cycle is acetylated
(65). It can also act as an energy source, undergoing β-oxidation
to acetyl-Coa in the colonocytes, which enters the TCA cycle.
The metabolomic analysis also revealed that in both groups 2′-FL
was partially absorbed and excreted unaltered in urine, indicating
that Lewis rats are secretory research animal models, as has been
reported previously (2, 66). Moreover, a higher content of fucose
was detected in urine samples of the 2′-FL group, suggesting
that the fucosidases of the microbiota efficiently liberated the
monosaccharide and this was later absorbed in the colon. Indeed,
several enteric bacteria have been shown to liberate fucose after
HMO degradation. However, although most of them are able to
metabolize the galactose and glucose forming part of the lactose,
they might not be able to process fucose, which is liberated and
subsequently absorbed by the gut (67, 68). Besides microbial
metabolites, other endogenous molecules were also present in
higher proportions in the urine, such as the metabolites of the
TCA cycle, indicating that 2′-FL also has an influence on the
host metabolism. Alternatively, considering the possibility that
SCFAs enter the TCA cycle of the colonic enterocytes and that
these metabolites produced in the gut end up in the urine, the
changes in the SCFA found by 2′-FL can also influence these TCA
cycle metabolites.
The mixture of oligosaccharides found in human milk has
been shown to influence gut immunity and microbiome. In
addition, it has to be taken into account that the administration
of a single bolus dose of 2′FL performed in this study does not
represent the typical exposure produced during breastfeeding,
and therefore, the obtained results should not be directly
extrapolated. Although a single HMO cannot mimic the
structural and functional complexity of the mixture, the effects of
individual oligosaccharides are relevant to be further elucidated
for future application to improve health in early life. In the
present study, the HMO 2′-FL was identified as having multiple
health benefits in early life. The relatively immature immune
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system of the newborn was shown to be more developed and
probably more prepared to fight infections, as depicted by a Th1-
biased phenotype in both cellular and humoral compartments.
Moreover, 2′-FL seems to promote immunoregulatory effects,
as it decreased the levels of inflammatory cytokines in the gut.
The higher Lactobacillus proportion in the fecal microbiota and
the higher proportion of the SCFA butyrate supports the pre-
biotic role of this oligosaccharide. Finally, 2′-FL not only induced
local effects, such as a trophic effect in the small intestine, but
it was also able to be metabolized by the microbiota, to arrive
at the systemic compartment and change the urinary metabolic
profile. Future experiments should evaluate the relationship
between the intestinal and systemic effects found here, as well
as gain a deeper insight into the host–microbiota crosstalk, in
order to decipher the mechanisms of action of 2′-FL, other
single HMO, but also the whole complex HMO mixture, in
early life.
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